Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
VYNE Therapeutics ( (VYNE) ) just unveiled an announcement.
VYNE Therapeutics’ stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing shares available for issuance and adjusting share recycling policies. During the annual meeting, all five proposals, including director elections and executive compensation, were approved, indicating strong shareholder support and potential for strategic growth.
More about VYNE Therapeutics
VYNE Therapeutics Inc. operates within the pharmaceutical industry, focusing on developing and commercializing therapies for dermatological conditions and other medical needs.
YTD Price Performance: 9.44%
Average Trading Volume: 84,606
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $37.62M
Find detailed analytics on VYNE stock on TipRanks’ Stock Analysis page.
